Imatinib Completed Phase 2 Trials for Graft Versus Host Disease (GVHD) / Scleroderma, Systemic Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01309997Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease